Business
Earth Science Tech, Inc. Finalizes Plans for Human Trials on New CBD-Based Formula Targeting Opioid Addiction Epidemic
Earth Science Tech, Inc. Finalizes Plans for Human Trials on New CBD-Based Formula Targeting Opioid Addiction Epidemic.
About this update from Earth Science Tech, Inc.
[{"type":"text","content":"\n\n DORAL, Fla., Feb. 28, 2018 (GLOBE NEWSWIRE) -- via NetworkWire – Earth Science Tech, Inc. (OTC:ETST) (“ETST\" or the “Company\"), an innovative biotech company focused on the cannabinoid (CBD), nutraceutical and pharmaceutical fields, as well as on R&D for certain medical devices, today announces that it has finalized the plans for its previously announced human trial to assess the efficacy of the combination of an essential mineral element and full-spectrum cannabinoid industrial hemp oil. The purpose of this nine-month trial is to develop a CBD formulation and methodology for treating opioid addicts, preventing fatal overdoses, and relieving side-effects from withdrawals.\n This formulation is expected to increase potency as opposed to the current status quo, which consists solely of essential mineral element therapy (monotherapy) in treating patients with morbid substance abuse and/or dependence. Globally, there are numerous, promising clinical studies on the potential of cannabinoids for the treatment of substance abuse and psychological disorders. ETST’s new study takes advantage of two of the properties of the Company’s full-spectrum cannabinoids industrial hemp oil that, based on positive feedback from customers and doctors, have demonstrated great success against addiction. ETST’s cannabinoids will be mixed with an essential mineral element, thereby potentially supporting and increasing the action of other drugs and medicinal substances. The human trial will study substance abuse patients who have undergone drug prescription treatment or dietary supplement monotherapy, full-spectrum cannabinoid monotherapy, and a combination of full-spectrum cannabinoids and a dietary supplement molecule. The patient will receive this treatment sequentially: the first three months with drug prescription treatment monotherapy or dietary supplement monotherapy; the second three months with drug prescription or dietary supplement combined with full-spectrum cannabinoids; and the final three months with full-spectrum cannabinoids.  The project will test the additive nature of full-spectrum cannabinoids with two different forms of an essential mineral element, which will be revealed soon. Should the potential synergies prove successful, ETST will be positioned to bring innovative new products ...